1,723 results on '"Chlebowski, Rowan T."'
Search Results
2. Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis
- Author
-
Chlebowski, Rowan T., Aragaki, Aaron K., Pan, Kathy, Mortimer, Joanne E., Johnson, Karen C., Wactawski-Wende, Jean, LeBoff, Meryl S., Lavasani, Sayeh, Lane, Dorothy, Nelson, Rebecca A., and Manson, JoAnn E.
- Published
- 2024
- Full Text
- View/download PDF
3. Long-term breast cancer incidence trends by mammography, obesity, and menopausal hormone therapy
- Author
-
Chlebowski, Rowan T. and Aragaki, Aaron K.
- Published
- 2024
- Full Text
- View/download PDF
4. Alcohol and Smoking Cessation as Potential Modulators for Smoking-Associated Psoriasis Risk in Postmenopausal Women: The Women’s Health Initiative
- Author
-
Li, Wendy, Chan, Alfred A, Han, Jiali, Chlebowski, Rowan T, and Lee, Delphine J
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Alcoholism ,Alcohol Use and Health ,Psoriasis ,Substance Misuse ,Prevention ,Cancer ,Tobacco ,Tobacco Smoke and Health ,Clinical Research ,Aging ,Respiratory ,Cardiovascular ,Stroke ,Good Health and Well Being ,Humans ,Female ,Aged ,United States ,Prospective Studies ,Smoking Cessation ,Smoking ,Postmenopause ,Medicare ,Women's Health ,Risk Factors ,Alcohol Drinking ,Clinical Sciences ,Dermatology & Venereal Diseases ,Clinical sciences - Abstract
BackgroundThe association of alcohol with psoriasis has been inconsistent among studies.ObjectivesWe aimed (1) to determine whether alcohol consumption (by status, frequency, and subtype of alcohol) modulates smoking-related psoriasis risk in postmenopausal women while stratifying for smoking status and pack-years and (2) to evaluate the effect of smoking cessation on psoriasis risk in postmenopausal women.MethodsThis prospective cohort study included 106,844 postmenopausal women enrolled in the Women's Health Initiative between 1993 and 1998. Patients diagnosed with psoriasis were identified using fee-for-service Medicare International Classification of Diseases, Ninth Revision, Clinical Modification codes assigned by dermatologists or rheumatologists. Self-administered questionnaires were used to obtain information on demographics, medical history, and smoking and alcohol habits. Hazard ratios from Cox regression models were adjusted for ethnicity, income, body mass index, and history of non-melanoma skin cancer and were stratified on age and on randomization status in the Women's Health Initiative study components.ResultsIn the initial statistical model, past and current alcohol drinkers had higher risks of psoriasis compared with never-drinkers (P-trend < 0.001). This association was not observed after adjusting for cigarette smoking (P-trend: 0.478). The effect of alcohol (by status, frequency, and alcohol subtype) isolated by stratifying the analysis by smoking status (i.e., among never smokers) showed no association with psoriasis. Smoking showed an increasing risk for psoriasis with greater pack-years compared with those who have never smoked (P-trend: < 0.001). Compared to smokers at baseline, past smokers had a lower risk of psoriasis across women who smoked 5-14 cigarettes per day (hazard ratio 0.67, 95% confidence interval 0.51-0.88) and across women who smoked for 5-24 years (hazard ratio 0.65, 95% confidence interval 0.46-0.90).ConclusionsThese findings indicate that alcohol consumption does not modulate smoking-related psoriasis risk. Cigarette smoking, but not alcohol consumption, is an independent risk factor for psoriasis in postmenopausal women. As greater pack-years was associated with a higher risk of psoriasis and smoking cessation was conversely associated with a lower risk of psoriasis for moderate smokers, a greater emphasis on smoking abstinence and cessation counseling may benefit patients who already have other risk factors for psoriasis.
- Published
- 2023
5. Cardiometabolic risk factors, physical activity, and postmenopausal breast cancer mortality: results from the Women’s Health Initiative
- Author
-
Dieli-Conwright, Christina M, Nelson, Rebecca A, Simon, Michael S, Irwin, Melinda L, Neuhouser, Marian L, Reding, Kerryn W, Crane, Tracy E, Manson, JoAnn E, Nassir, Rami, Shadyab, Aladdin H, LaMonte, Michael, Qi, Lihing, Thomson, Cynthia A, Kroenke, Candyce H, Pan, Kathy, Chlebowski, Rowan T, and Mortimer, Joanne
- Subjects
Biomedical and Clinical Sciences ,Health Services and Systems ,Health Sciences ,Public Health ,Oncology and Carcinogenesis ,Nutrition ,Aging ,Cardiovascular ,Prevention ,Cancer ,Breast Cancer ,Aetiology ,2.1 Biological and endogenous factors ,Metabolic and endocrine ,Good Health and Well Being ,Breast Neoplasms ,Cardiometabolic Risk Factors ,Exercise ,Female ,Humans ,Metabolic Syndrome ,Postmenopause ,Proportional Hazards Models ,Risk Factors ,Women's Health ,Physical activity ,Metabolic syndrome ,Breast cancer ,Nursing ,Paediatrics and Reproductive Medicine ,Public Health and Health Services ,Obstetrics & Reproductive Medicine ,Reproductive medicine ,Midwifery ,Public health - Abstract
BackgroundHigher physical activity levels are associated with lower breast cancer-specific mortality. In addition, the metabolic syndrome is associated with higher breast cancer-specific mortality. Whether the physical activity association with breast cancer mortality is modified by number of metabolic syndrome components (cardiometabolic risk factors) in postmenopausal women with early-stage breast cancer remains unknown.MethodsCardiovascular risk factors included high waist circumference, hypertension, high cholesterol, and diabetes. Breast cancers were verified by medical record review. Mortality finding were enhanced by serial National Death Index queries. Cox proportional hazards regression models were used to estimate associations between baseline physical activity and subsequent breast cancer-specific and overall mortality following breast cancer diagnosis in Women's Health Initiative participants. These associations were examined after stratifying by cardiometabolic risk factor group.ResultsAmong 161,308 Women's Health Initiative (WHI) participants, 8543 breast cancers occurred after 9.5 years (median) follow-up in women, additionally with information on cardiometabolic risk factors and physical activity at entry. In multi-variable analyses, as measured from cancer diagnosis, higher physical activity levels were associated with lower all-cause mortality risk (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.78-0.95, trend P
- Published
- 2022
6. Changes in physical function in older women with endometrial cancer with or without adjuvant therapy
- Author
-
Quick, Allison M., McLaughlin, Eric, Krok Schoen, Jessica L., Felix, Ashley S., Presley, Carolyn J., Cespedes Feliciano, Elizabeth M., Shadyab, Aladdin H., Jung, Su Yon, Luo, Juhua, King, Jennifer J., Rapp, Stephen R., Werts, Samantha, Chlebowski, Rowan T., Naughton, Michelle, and Paskett, Electra
- Published
- 2023
- Full Text
- View/download PDF
7. MRI Based Validation of Abdominal Adipose Tissue Measurements From DXA in Postmenopausal Women
- Author
-
Bea, Jennifer W, Chen, Zhao, Blew, Robert M, Nicholas, Jennifer Skye, Follis, Shawna, Bland, Victoria L, Cheng, Ting-Yuan David, Ochs-Balcom, Heather M, Wactawski-Wende, Jean, Banack, Hailey R, Neuhouser, Marian L, Laddu, Deepika, Stefanick, Marcia L, Cauley, Jane A, Caan, Bette, LeBoff, Meryl S, Chlebowski, Rowan T, and Odegaard, Andrew O
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Bioengineering ,Biomedical Imaging ,Aging ,Prevention ,Absorptiometry ,Photon ,Adipose Tissue ,Aged ,Female ,Humans ,Intra-Abdominal Fat ,Magnetic Resonance Imaging ,Middle Aged ,Postmenopause ,Subcutaneous Fat ,Dual-energy X-ray absorptiometry ,body composition ,visceral fat ,subcutaneous fat ,magnetic resonance imaging ,Arthritis & Rheumatology ,Clinical sciences - Abstract
IntroductionVisceral adipose tissue (VAT) is a hypothesized driver of chronic disease. Dual-energy X-ray absorptiometry (DXA) potentially offers a lower cost and more available alternative compared to gold-standard magnetic resonance imaging (MRI) for quantification of abdominal fat sub-compartments, VAT and subcutaneous adipose tissue (SAT). We sought to validate VAT and SAT area (cm2) from historical DXA scans against MRI.MethodologyParticipants (n = 69) from the Women's Health Initiative (WHI) completed a 3 T MRI scan and a whole body DXA scan (Hologic QDR2000 or QDR4500; 2004-2005). A subset of 43 participants were scanned on both DXA devices. DXA-derived VAT and SAT at the 4th lumbar vertebrae (5 cm wide) were analyzed using APEX software (v4.0, Hologic, Inc., Marlborough, MA). MRI VAT and SAT areas for the corresponding DXA region of interest were quantified using sliceOmatic software (v5.0, Tomovision, Magog, Canada). Pearson correlations between MRI and DXA-derived VAT and SAT were computed, and a Bland-Altman analysis was performed.ResultsParticipants were primarily non-Hispanic white (86%) with a mean age of 70.51 ± 5.79 years and a mean BMI of 27.33 ± 5.40 kg/m2. Correlations between MRI and DXA measured VAT and SAT were 0.90 and 0.92, respectively (p ≤ 0.001). Bland-Altman plots showed that DXA-VAT slightly overestimated VAT on the QDR4500 (-3.31 cm2); this bias was greater in the smaller subset measured on the older DXA model (QDR2000; -30.71 cm2). The overestimation of DXA-SAT was large (-85.16 to -118.66 cm2), but differences were relatively uniform for the QDR4500.ConclusionsNew software applied to historic Hologic DXA scans provide estimates of VAT and SAT that are well-correlated with criterion MRI among postmenopausal women.
- Published
- 2022
8. Chronic Oxidative Stress as a Marker of Long-term Radiation-Induced Cardiovascular Outcomes in Breast Cancer
- Author
-
Vasbinder, Alexi, Cheng, Richard K., Heckbert, Susan R., Thompson, Hilaire, Zaslavksy, Oleg, Chlebowski, Rowan T., Shadyab, Aladdin H., Johnson, Lisa, Wactawski-Wende, Jean, Wells, Gretchen, Yung, Rachel, Martin, Lisa Warsinger, Paskett, Electra D., and Reding, Kerryn
- Published
- 2023
- Full Text
- View/download PDF
9. Dietary Intervention Favorably Influences Physical Functioning: The Women’s Health Initiative Randomized Dietary Modification Trial
- Author
-
Chlebowski, Rowan T., Aragaki, Aaron K., Pan, Kathy, Nelson, Rebecca A., Barac, Ana, Manson, JoAnn E., Stefanick, Marcia L., Ikramuddin, Farha S., Johnson, Karen C., Krok-Schoen, Jessica L., Laddu, Deepika, Pichardo, Margaret S., Snetselaar, Linda G., LeBoff, Meryl S., and Michael, Yvonne
- Published
- 2024
- Full Text
- View/download PDF
10. Metabolic syndrome risk components and mortality after triple‐negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative
- Author
-
Yuan, Yuan, Pan, Kathy, Mortimer, Joanne, Chlebowski, Rowan T, Luo, Juhua, Yan, Jessica E, Yost, Susan E, Kroenke, Candyce H, Adams‐Campbell, Lucile, Nassir, Rami, Sun, Yangbo, Shadyab, Aladdin H, Vitolins, Mara Z, Saquib, Nazmus, Wild, Robert A, Manson, JoAnn E, and Nelson, Rebecca A
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Health Sciences ,Oncology and Carcinogenesis ,Nutrition ,Aging ,Clinical Research ,Breast Cancer ,Cancer ,Prevention ,Good Health and Well Being ,Female ,Humans ,Metabolic Syndrome ,Postmenopause ,Risk Factors ,Triple Negative Breast Neoplasms ,Women's Health ,metabolic syndrome ,postmenopausal women ,risk factors ,triple-negative breast cancer ,Women's Health Initiative ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Public health - Abstract
BackgroundTriple-negative breast cancer (TNBC) has a high recurrence risk and poor clinical outcomes. Associations between metabolic syndrome (MetS) risk components and mortality in postmenopausal women with TNBC were examined in the Women's Health Initiative.MethodsFive hundred forty-four postmenopausal women were diagnosed with nonmetastatic TNBC. Baseline risk components included a high waist circumference (≥88 cm), high blood pressure, hypercholesterolemia, and diabetes. Groups were categorized by the number of MetS risk components: none, 1 or 2, or 3 or 4. Hazard ratios (HRs) and 95% confidence intervals (CIs) across groups were computed with multivariable adjusted Cox models. Outcomes included breast cancer-specific mortality and breast cancer overall mortality (breast cancer followed by death from any cause). Variables in the multivariable model included age at TNBC diagnosis; race/ethnicity; income; education; clinical/observational trial status; history of oral contraceptive, hormone, and/or statin use; cancer stage; and chemotherapy and/or radiation treatment status.ResultsOf the 544 participants with TNBC, 33% had no MetS risk components (n = 178), 59% had 1 or 2 risk components (n = 323), and 8% had 3 or 4 risk components (n = 43). After a median follow-up from diagnosis of 8.3 years, multivariable results showed that women with 3 or 4 risk components had a nonsignificantly higher risk of breast cancer mortality (HR, 2.05; 95% CI, 0.94-4.47 trend P = .114) and a significantly higher risk of overall mortality (HR, 2.13; 95% CI, 1.22-3.71; trend P = .006) versus women with 0 risk components.ConclusionsPostmenopausal women with TNBC and 3 or 4 MetS risk components have a nonsignificantly higher breast cancer mortality risk and a significantly higher overall mortality risk, likely because of negative influences of metabolic risk factors on several causes of death.
- Published
- 2021
11. Metabolomics Biomarkers for Fatty Acid Intake and Biomarker-Calibrated Fatty Acid Associations with Chronic Disease Risk in Postmenopausal Women
- Author
-
Prentice, Ross L, Vasan, Sowmya, Tinker, Lesley F, Neuhouser, Marian L, Navarro, Sandi L, Raftery, Daniel, Gowda, GA Nagana, Pettinger, Mary, Aragaki, Aaron K, Lampe, Johanna W, Huang, Ying, Van Horn, Linda, Manson, JoAnn E, Wallace, Robert B, Mossavar-Rahmani, Yasmin, Wactawski-Wende, Jean, Liu, Simin, Snetselaar, Linda, Howard, Barbara V, Chlebowski, Rowan T, and Zheng, Cheng
- Published
- 2023
- Full Text
- View/download PDF
12. Metabolomics-Based Biomarker for Dietary Fat and Associations with Chronic Disease Risk in Postmenopausal Women
- Author
-
Prentice, Ross L., Vasan, Sowmya, Tinker, Lesley F., Neuhouser, Marian L., Navarro, Sandi L., Raftery, Daniel, Gowda, GA Nagana, Pettinger, Mary, Aragaki, Aaron K., Lampe, Johanna W., Huang, Ying, Van Horn, Linda, Manson, JoAnn E., Wallace, Robert, Mossavar-Rahmani, Yasmin, Wactawski-Wende, Jean, Liu, Simin, Snetselaar, Linda, Howard, Barbara V., Chlebowski, Rowan T., and Zheng, Cheng
- Published
- 2023
- Full Text
- View/download PDF
13. Calcium Intake and Lung Cancer Risk: A Pooled Analysis of 12 Prospective Cohort Studies
- Author
-
Takata, Yumie, Yang, Jae Jeong, Yu, Danxia, Smith-Warner, Stephanie A., Blot, William J., White, Emily, Robien, Kimberly, Prizment, Anna, Wu, Kana, Sawada, Norie, Lan, Qing, Park, Yikyung, Gao, Yu-Tang, Cai, Qiuyin, Song, Mingyang, Zhang, Xuehong, Pan, Kathy, Agudo, Antonio, Panico, Salvatore, Liao, Linda M., Tsugane, Shoichiro, Chlebowski, Rowan T., Nøst, Therese Haugdahl, Schulze, Matthias B., Johannson, Mattias, Zheng, Wei, and Shu, Xiao-Ou
- Published
- 2023
- Full Text
- View/download PDF
14. Racial differences in anthropometric measures as risk factors for triple-negative breast cancer
- Author
-
Wang, Fengge, Kroenke, Candyce H., Pan, Kathy, Shadyab, Aladdin H., Chlebowski, Rowan T., Wactawski-Wende, Jean, Qi, Lihong, and Luo, Juhua
- Published
- 2022
- Full Text
- View/download PDF
15. Association between baseline insulin resistance and psoriasis incidence: the Women’s Health Initiative
- Author
-
Chan, Alfred A., Li, Houmin, Li, Wendy, Pan, Kathy, Yee, Jennifer K., Chlebowski, Rowan T., and Lee, Delphine J.
- Published
- 2022
- Full Text
- View/download PDF
16. Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials.
- Author
-
Prentice, Ross L, Aragaki, Aaron K, Chlebowski, Rowan T, Zhao, Shanshan, Anderson, Garnet L, Rossouw, Jacques E, Wallace, Robert, Banack, Hailey, Shadyab, Aladdin H, Qi, Lihong, Snively, Beverly M, Gass, Margery, and Manson, JoAnn E
- Subjects
Humans ,Gallbladder Diseases ,Cardiovascular Diseases ,Estrogens ,Conjugated (USP) ,Estrogen Replacement Therapy ,Incidence ,Risk Factors ,Postmenopause ,Aged ,Middle Aged ,United States ,Female ,Fractures ,Bone ,Randomized Controlled Trials as Topic ,Medroxyprogesterone Acetate ,Intention to Treat Analysis ,Cox model ,cancer ,cardiovascular disease ,diabetes ,dual outcomes ,fractures ,hazard ratio ,menopausal hormone therapy ,Clinical Research ,Clinical Trials and Supportive Activities ,Estrogen ,Contraception/Reproduction ,Aging ,Good Health and Well Being ,Mathematical Sciences ,Medical and Health Sciences ,Epidemiology - Abstract
Dual-outcome intention-to-treat hazard rate analyses have potential to complement single-outcome analyses for the evaluation of treatments or exposures in relation to multivariate time-to-response outcomes. Here we consider pairs formed from important clinical outcomes to obtain further insight into influences of menopausal hormone therapy on chronic disease. As part of the Women's Health Initiative, randomized, placebo-controlled hormone therapy trials of conjugated equine estrogens (CEE) among posthysterectomy participants and of these same estrogens plus medroxyprogesterone acetate (MPA) among participants with an intact uterus were carried out at 40 US clinical centers (1993-2016). These data provide the context for analyses covering the trial intervention periods and a nearly 20-year (median) cumulative duration of follow-up. The rates of multiple outcome pairs were significantly influenced by hormone therapy, especially over cumulative follow-up, providing potential clinical and mechanistic insights. For example, among women randomized to either regimen, hazard ratios for pairs defined by fracture during intervention followed by death from any cause were reduced and hazard ratios for pairs defined by gallbladder disease followed by death were increased, though these findings may primarily reflect single-outcome associations. In comparison, hazard ratios for diabetes followed by death were reduced with CEE but not with CEE + MPA, and those for hypertension followed by death were increased with CEE + MPA but not with CEE.
- Published
- 2020
17. The association between DXA‐derived body fat measures and breast cancer risk among postmenopausal women in the Women's Health Initiative
- Author
-
Arthur, Rhonda S, Xue, Xiaonan, Kamensky, Victor, Chlebowski, Rowan T, Simon, Michael, Luo, Juhua, Shadyab, Aladdin H, Neuhouser, Marian L, Banack, Hailey, Ho, Gloria YF, Lane, Dorothy S, Pan, Kathy, Reding, Kerryn W, Wassertheil‐Smoller, Sylvia, Dannenberg, Andrew J, and Rohan, Thomas E
- Subjects
Prevention ,Breast Cancer ,Nutrition ,Obesity ,Estrogen ,Cancer ,Aging ,Clinical Research ,Absorptiometry ,Photon ,Adipose Tissue ,Adiposity ,Body Mass Index ,Breast ,Breast Neoplasms ,Female ,Follow-Up Studies ,Humans ,Incidence ,Middle Aged ,Neoplasm Invasiveness ,Odds Ratio ,Postmenopause ,Risk Assessment ,Risk Factors ,United States ,body fat ,breast cancer risk ,postmenopausal women ,Biochemistry and Cell Biology ,Oncology and Carcinogenesis - Abstract
BackgroundMost studies demonstrating an association between excess adiposity and postmenopausal breast cancer have used anthropometric measures, particularly body mass index (BMI). However, more direct body fat measures may more accurately determine the relationship between body fat distribution and breast cancer risk.MethodsCox proportional hazards regression models were created to examine the associations of dual-energy x-ray absorptiometry (DXA) body fat measures (at baseline and during follow-up) with breast cancer risk among 10 931 postmenopausal women from the Women's Health Initiative cohort. A total of 639 incident invasive breast cancer cases (including 484 estrogen receptor positive (ER+) cases) were ascertained after a median follow-up of 15.0 years.ResultsExcess whole body fat mass and trunk fat mass were positively associated with risk invasive breast cancer risk. These associations persisted even after additional adjustment for standard anthropometric measures. In time-dependent analyses, we observed that both whole body fat mass and trunk fat mass, in the highest versus lowest category, were associated with a doubling of risk of invasive breast cancer overall (HR: 2.17; 95% CI: 1.54-3.05 and 2.20; 1.55-3.14, respectively) and of ER+ breast cancer (2.05; 1.37-3.05 and 2.03; 1.34-3.07, respectively). The remaining DXA measures were also positively associated with breast cancer risk in baseline and time-dependent analyses.ConclusionThese findings suggest that DXA-derived body fat measures are positively associated with breast cancer risk after adjustment for BMI and other conventional breast cancer risk factors.
- Published
- 2020
18. Insulin Resistance and Cancer-Specific and All-Cause Mortality in Postmenopausal Women: The Women’s Health Initiative
- Author
-
Pan, Kathy, Nelson, Rebecca A, Wactawski-Wende, Jean, Lee, Delphine J, Manson, JoAnn E, Aragaki, Aaron K, Mortimer, Joanne E, Phillips, Lawrence S, Rohan, Thomas, Ho, Gloria YF, Saquib, Nazmus, Shadyab, Aladdin H, Nassir, Rami, Rhee, Jinnie J, Hurria, Arti, and Chlebowski, Rowan T
- Subjects
Prevention ,Aging ,Diabetes ,Nutrition ,Cancer ,Metabolic and endocrine ,Good Health and Well Being ,Aged ,Aged ,80 and over ,Body Mass Index ,Cause of Death ,Female ,Follow-Up Studies ,Humans ,Insulin Resistance ,Middle Aged ,Neoplasms ,Postmenopause ,Proportional Hazards Models ,Public Health Surveillance ,Risk Factors ,United States ,Women's Health ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
BackgroundInsulin resistance has been proposed as a mediator of the increased cancer incidence and mortality associated with obesity. However, prior studies included limited cancer deaths and had inconsistent findings. Therefore, we evaluated insulin resistance and cancer-specific and all-cause mortality in postmenopausal women participating in the Women's Health Initiative (WHI).MethodsEligible were a subsample of 22 837 WHI participants aged 50-79 years enrolled at 40 US clinical centers from 1993 to 1998 who had baseline fasting glucose and insulin levels. Baseline insulin resistance was measured by the homeostasis model assessment of insulin resistance (HOMA-IR). Cancers were verified by central medical record review and deaths verified by medical record and death certificate review enhanced by National Death Index queries. Cox proportional hazards regression models were used to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer-specific and all-cause mortality. All statistical tests were two-sided.ResultsDuring a median of 18.9 years of follow-up, 1820 cancer deaths and 7415 total deaths occurred. Higher HOMA-IR quartile was associated with higher cancer-specific mortality (Q4 vs Q1, HR = 1.26, 95% CI = 1.09 to 1.47; Ptrend = .003) and all-cause mortality (Q4 vs Q1, HR = 1.63, 95% CI = 1.51 to 1.76; Ptrend < .001). A sensitivity analysis for diabetes status did not change findings. Among women with body mass index less than 25 kg/m2, higher HOMA-IR quartile was associated with higher cancer mortality (Fine and Gray, P = .004).ConclusionsHigh insulin resistance, as measured by HOMA-IR, identifies postmenopausal women at higher risk for cancer-specific and all-cause mortality who could potentially benefit from early intervention.
- Published
- 2020
19. Low-fat dietary pattern and global cognitive function: Exploratory analyses of the Women's Health Initiative (WHI) randomized Dietary Modification trial.
- Author
-
Chlebowski, Rowan T, Rapp, Steve, Aragaki, Aaron K, Pan, Kathy, Neuhouser, Marian L, Snetselaar, Linda G, Manson, JoAnn E, Wactawski-Wende, Jean, Johnson, Karen C, Hayden, Kathleen, Baker, Laura D, Henderson, Victor W, Garcia, Lorena, Qi, Lihong, and Prentice, Ross L
- Subjects
Cognition ,Dietary modification ,Low-fat dietary pattern ,Randomized clinical trial ,Women's Health Initiative ,Womens Health Initiative - Abstract
Background:Meta-analyses of observational studies associate adherence to several dietary patterns with cognitive health. However, limited evidence from full scale, randomized controlled trials precludes causal inference regarding dietary effects on cognitive function. Methods:The Women's Health Initiative (WHI) Dietary Modification (DM) randomized trial, in 48,835 postmenopausal women, included a subset of 1,606 WHI Memory Study (WHIMS) participants >= 65 years old, to assess low-fat dietary pattern influence on global cognitive function, evaluated with annual screening (Modified Mini-Mental State Examinations [3MSE]). Participants were randomized by a computerized, permuted block algorithm, stratified by age group and center, to a dietary intervention (40%) to reduce fat intake to 20% of energy and increase fruit, vegetable and grain intake or usual diet comparison groups (60%). The study outcome was possible cognition impairment (failed cognitive function screening) through the 8.5 year (median) dietary intervention. Those failing screening received a comprehensive, multi-phase cognitive function assessment to classify as: no cognitive impairment, mild cognitive impairment, or probable dementia. Exploratory analyses examined the composite endpoint of death after possible cognitive impairment through 18.7 years (median) follow-up. The WHI trials are registered at ClinicalTrials.gov:NCT00000611. Findings:Among the 1,606 WHIMS participants, the dietary intervention statistically significantly reduced the incidence of possible cognitive impairment (n = 126; hazard ratio [HR] 0.59 95% confidence interval [CI] 0.38-0. 91, P = 0.01) with HR for dietary influence on subsequent mild cognitive impairment of 0.65 (95% CI 0.35-1.19) and HR of 0.63 (95% CI 0.19-2.10) for probable dementia (PD). Through 18.7 years, deaths from all-causes after possible cognitive impairment were non-significantly lower in the dietary intervention group (0.56% vs 0.77%, HR 0.83 95% CI 0.35 to 2.00, P = 0.16). Interpretation:Adoption of a low-fat eating pattern, representing dietary moderation, significantly reduced risk of possible cognitive impairment in postmenopausal women. Funding:Several Institutes of the US National Institutes of Health.
- Published
- 2020
20. Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial
- Author
-
Pan, Kathy, Aragaki, Aaron K., Michael, Yvonne, Thomson, Cynthia A., Snetselaar, Linda G., Wactawski-Wende, Jean, Garcia, David O., Dieli-Conwright, Christina M., Shadyab, Aladdin H., Saquib, Nazmus, and Chlebowski, Rowan T.
- Published
- 2022
- Full Text
- View/download PDF
21. Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women’s Health Initiative
- Author
-
Chlebowski, Rowan T., primary, Aragaki, Aaron K., additional, Pan, Kathy, additional, Simon, Michael S., additional, Neuhouser, Marian L., additional, Haque, Reina, additional, Rohan, Thomas E., additional, Wactawski‐Wende, Jean, additional, Orchard, Tonya S., additional, Mortimer, Joanne E., additional, Lane, Dorothy, additional, Kaunitz, Andrew M., additional, Desai, Pinkal, additional, Wild, Robert A., additional, Barac, Ana, additional, and Manson, JoAnn E., additional
- Published
- 2024
- Full Text
- View/download PDF
22. The Women’s Health Initiative Randomized Trials and Clinical Practice
- Author
-
Manson, JoAnn E., primary, Crandall, Carolyn J., additional, Rossouw, Jacques E., additional, Chlebowski, Rowan T., additional, Anderson, Garnet L., additional, Stefanick, Marcia L., additional, Aragaki, Aaron K., additional, Cauley, Jane A., additional, Wells, Gretchen L., additional, LaCroix, Andrea Z., additional, Thomson, Cynthia A., additional, Neuhouser, Marian L., additional, Van Horn, Linda, additional, Kooperberg, Charles, additional, Howard, Barbara V., additional, Tinker, Lesley F., additional, Wactawski-Wende, Jean, additional, Shumaker, Sally A., additional, and Prentice, Ross L., additional
- Published
- 2024
- Full Text
- View/download PDF
23. The Womenʼs Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context
- Author
-
Chlebowski, Rowan T. and Aragaki, Aaron K.
- Published
- 2023
- Full Text
- View/download PDF
24. Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial.
- Author
-
Manson, JoAnn E, Aragaki, Aaron K, Bassuk, Shari S, Chlebowski, Rowan T, Anderson, Garnet L, Rossouw, Jacques E, Howard, Barbara V, Thomson, Cynthia A, Stefanick, Marcia L, Kaunitz, Andrew M, Crandall, Carolyn J, Eaton, Charles B, Henderson, Victor W, Liu, Simin, Luo, Juhua, Rohan, Thomas, Shadyab, Aladdin H, Wells, Gretchen, Wactawski-Wende, Jean, and Prentice, Ross L
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Clinical Sciences ,Aging ,Estrogen ,Clinical Trials and Supportive Activities ,Contraception/Reproduction ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Age Factors ,Aged ,Breast Neoplasms ,Cause of Death ,Colorectal Neoplasms ,Coronary Disease ,Estrogen Replacement Therapy ,Estrogens ,Conjugated (USP) ,Female ,Follow-Up Studies ,Hip Fractures ,Humans ,Incidence ,Menopause ,Middle Aged ,Ovariectomy ,Pulmonary Embolism ,Stroke ,United States ,WHI Investigators ,Medical and Health Sciences ,General & Internal Medicine ,Clinical sciences - Abstract
BackgroundWhether health outcomes of menopausal estrogen therapy differ between women with and without bilateral salpingo-oophorectomy (BSO) is unknown.ObjectiveTo examine estrogen therapy outcomes by BSO status, with additional stratification by 10-year age groups.DesignSubgroup analyses of the randomized Women's Health Initiative Estrogen-Alone Trial. (ClinicalTrials.gov: NCT00000611).Setting40 U.S. clinical centers.Participants9939 women aged 50 to 79 years with prior hysterectomy and known oophorectomy status.InterventionConjugated equine estrogens (CEE) (0.625 mg/d) or placebo for a median of 7.2 years.MeasurementsIncidence of coronary heart disease and invasive breast cancer (the trial's 2 primary end points), all-cause mortality, and a "global index" (these end points plus stroke, pulmonary embolism, colorectal cancer, and hip fracture) during the intervention phase and 18-year cumulative follow-up.ResultsThe effects of CEE alone did not differ significantly according to BSO status. However, age modified the effect of CEE in women with prior BSO. During the intervention phase, CEE was significantly associated with a net adverse effect (hazard ratio for global index, 1.42 [95% CI, 1.09 to 1.86]) in older women (aged ≥70 years), but the global index was not elevated in younger women (P trend by age = 0.016). During cumulative follow-up, women aged 50 to 59 years with BSO had a treatment-associated reduction in all-cause mortality (hazard ratio, 0.68 [CI, 0.48 to 0.96]), whereas older women with BSO had no reduction (P trend by age = 0.034). There was no significant association between CEE and outcomes among women with conserved ovaries, regardless of age.LimitationsThe timing of CEE in relation to BSO varied; several comparisons were made without adjustment for multiple testing.ConclusionThe effects of CEE did not differ by BSO status in the overall cohort, but some findings varied by age. Among women with prior BSO, in those aged 70 years or older, CEE led to adverse effects during the treatment period, whereas women randomly assigned to CEE before age 60 seemed to derive mortality benefit over the long term.Primary funding sourceThe WHI program is funded by the National Heart, Lung, and Blood Institute; National Institutes of Health; and U.S. Department of Health and Human Services. Wyeth Ayerst donated the study drugs.
- Published
- 2019
25. Self-reported symptoms among cancer survivors in the Women’s Health Initiative (WHI) Life and Longevity after Cancer (LILAC) cohort
- Author
-
Bernardo, Brittany M., Pennell, Michael L., Naughton, Michelle J., Brodin, Nils Patrik, Neuhouser, Marian L., Chlebowski, Rowan T., and Paskett, Electra D.
- Published
- 2022
- Full Text
- View/download PDF
26. Sleep medication use and risk of fractures in breast cancer survivors
- Author
-
Haque, Reina, Chlebowski, Rowan T., and Chen, LieHong
- Published
- 2021
- Full Text
- View/download PDF
27. Stratified Probabilistic Bias Analysis for Body Mass Index–related Exposure Misclassification in Postmenopausal Women
- Author
-
Banack, Hailey R, Stokes, Andrew, Fox, Matthew P, Hovey, Kathleen M, Cespedes Feliciano, Elizabeth M, LeBlanc, Erin S, Bird, Chloe, Caan, Bette J, Kroenke, Candyce H, Allison, Matthew A, Going, Scott B, Snetselaar, Linda, Cheng, Ting-Yuan David, Chlebowski, Rowan T, Stefanick, Marcia L, LaMonte, Michael J, and Wactawski-Wende, Jean
- Subjects
Epidemiology ,Public Health ,Health Sciences ,Clinical Research ,Obesity ,Aging ,Nutrition ,Stroke ,Cancer ,Good Health and Well Being ,Adipose Tissue ,Aged ,Bias ,Body Height ,Body Mass Index ,Body Weight ,Female ,Humans ,Middle Aged ,Postmenopause ,Probability ,Bias analysis ,Body mass index ,Statistics ,Public Health and Health Services ,Public health - Abstract
BackgroundThere is widespread concern about the use of body mass index (BMI) to define obesity status in postmenopausal women because it may not accurately represent an individual's true obesity status. The objective of the present study is to examine and adjust for exposure misclassification bias from using an indirect measure of obesity (BMI) compared with a direct measure of obesity (percent body fat).MethodsWe used data from postmenopausal non-Hispanic black and non-Hispanic white women in the Women's Health Initiative (n=126,459). Within the Women's Health Initiative, a sample of 11,018 women were invited to participate in a sub-study involving dual-energy x-ray absorptiometry scans. We examined indices of validity comparing BMI-defined obesity (≥30 kg/m), with obesity defined by percent body fat. We then used probabilistic bias analysis models stratified by age and race to explore the effect of exposure misclassification on the obesity-mortality relationship.ResultsValidation analyses highlight that using a BMI cutpoint of 30 kg/m to define obesity in postmenopausal women is associated with poor validity. There were notable differences in sensitivity by age and race. Results from the stratified bias analysis demonstrated that failing to adjust for exposure misclassification bias results in attenuated estimates of the obesity-mortality relationship. For example, in non-Hispanic white women 50-59 years of age, the conventional risk difference was 0.017 (95% confidence interval = 0.01, 0.023) and the bias-adjusted risk difference was 0.035 (95% simulation interval = 0.028, 0.043).ConclusionsThese results demonstrate the importance of using quantitative bias analysis techniques to account for nondifferential exposure misclassification of BMI-defined obesity. See video abstract at, http://links.lww.com/EDE/B385.
- Published
- 2018
28. Association between Dietary Energy Density and Obesity-Associated Cancer: Results from the Women’s Health Initiative
- Author
-
Thomson, Cynthia A, Crane, Tracy E, Garcia, David O, Wertheim, Betsy C, Hingle, Melanie, Snetselaar, Linda, Datta, Mridul, Rohan, Thomas, LeBlanc, Erin, Chlebowski, Rowan T, and Qi, Lihong
- Subjects
Public Health ,Biomedical and Clinical Sciences ,Nutrition and Dietetics ,Health Sciences ,Cancer ,Clinical Trials and Supportive Activities ,Nutrition ,Clinical Research ,Prevention ,Obesity ,Aging ,Cardiovascular ,Metabolic and endocrine ,Oral and gastrointestinal ,Stroke ,Aged ,Body Mass Index ,Clinical Trials as Topic ,Diet ,Energy Intake ,Female ,Humans ,Middle Aged ,Neoplasms ,Observational Studies as Topic ,Postmenopause ,Prospective Studies ,Risk Factors ,Waist Circumference ,Weight Gain ,Women's Health ,Energy density ,Postmenopausal women ,Clinical Sciences ,Anthropology ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundDietary energy density (DED) is the ratio of energy (kilocalories or kilojoules) intake to food weight (grams) and is a measure of diet quality. Consumption of foods high in DED has been associated with weight gain in adults.ObjectiveTo investigate the association between baseline DED and incident obesity-associated cancers in the Women's Health Initiative.DesignProspective cohort study of clinical trial and observational study participants.Participants/settingPostmenopausal women aged 50 to 79 years (N=92,295) enrolled in the observational study or the calcium and vitamin D trial and hormone replacement therapy trials of the Women's Health Initiative.Main outcome measuresIncident, medical record-adjudicated, obesity-related cancers during follow-up. Exposure variable was DED (kilocalories per gram for the total diet) from self-reported dietary intake at baseline using a food frequency questionnaire.Statistical analysesThe associations between DED and each incident cancer, or any obesity-related cancer, were examined using competing-risks regression models, with death as a competing risk. Body mass index-stratified models were generated to investigate body mass index as a potential modifying factor.ResultsDED was associated with higher body mass index (28.9±6.0 vs 26.3±4.9) and waist circumference (89.3±14.2 vs 82.4±12.4 cm) for DED quintiles 5 vs 1, respectively. DED was associated with a 10% increased risk of any obesity-related cancer (subhazard ratioQ5 vs Q1: 1.1, 95% CI 1.03 to 1.2; P=0.004). This increased risk appeared limited to women who were normal weight at enrollment.ConclusionsHigher DED may be a contributing factor for obesity-related cancers, especially among normal-weight postmenopausal women and, as such, could serve as a modifiable behavior for dietary interventions to reduce obesity-associated cancer risk.
- Published
- 2018
29. Serum 25-hydroxyvitamin D concentrations and lung cancer risk in never-smoking postmenopausal women
- Author
-
Cheng, Ting-Yuan David, Song, Xiaoling, Beresford, Shirley AA, Ho, Gloria YF, Johnson, Karen C, Datta, Mridul, Chlebowski, Rowan T, Wactawski-Wende, Jean, Qi, Lihong, and Neuhouser, Marian L
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Prevention ,Complementary and Integrative Health ,Nutrition ,Clinical Research ,Lung ,Lung Cancer ,Adenocarcinoma ,Aged ,Carcinoma ,Non-Small-Cell Lung ,Case-Control Studies ,Female ,Humans ,Logistic Models ,Lung Neoplasms ,Middle Aged ,Odds Ratio ,Postmenopause ,Risk Factors ,Vitamin D ,25-Hydroxyvitamin D ,Lung cancer ,Postmenopausal women ,Never smokers ,Histology ,Public Health and Health Services ,Epidemiology ,Oncology and carcinogenesis - Abstract
PurposeVitamin D has been implicated in lowering lung cancer risk, but serological data on the association among never-smoking women are limited. We report results examining the association of serum 25-hydroxyvitamin D [25(OH)D] concentrations with lung cancer risk among female never smokers. We also examined whether the association was modified by vitamin D supplementation and serum vitamin A concentrations.MethodsIn the Women's Health Initiative, including the calcium/vitamin D (CaD) Trial, we selected 298 incident cases [191 non-small cell lung cancer (NSCLC) including 170 adenocarcinoma] and 298 matched controls of never smokers. Baseline serum 25(OH)D was assayed by a chemiluminescent method. Logistic regression was used to estimate odds ratios (ORs) for quartiles and predefined clinical cutoffs of serum 25(OH)D concentrations.ResultsComparing quartiles 4 versus 1 of serum 25(OH)D concentrations, ORs were 1.06 [95% confidence interval (CI) 0.61-1.84] for all lung cancer, 0.94 (95% CI 0.52-1.69) for NSCLC, and 0.91 (95% CI 0.49-1.68) for adenocarcinoma. Comparing serum 25(OH)D ≥ 75 (high) versus
- Published
- 2017
30. Low-fat dietary pattern and breast cancer mortality by metabolic syndrome components: a secondary analysis of the Women’s Health Initiative (WHI) randomised trial
- Author
-
Pan, Kathy, Aragaki, Aaron K., Neuhouser, Marian L., Simon, Michael S., Luo, Juhua, Caan, Bette, Snetselaar, Linda, Mortimer, Joanne E., Manson, JoAnn E., Kroenke, Candyce, Lane, Dorothy, Reding, Kerryn, Rohan, Thomas E., and Chlebowski, Rowan T.
- Published
- 2021
- Full Text
- View/download PDF
31. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials
- Author
-
Manson, JoAnn E, Aragaki, Aaron K, Rossouw, Jacques E, Anderson, Garnet L, Prentice, Ross L, LaCroix, Andrea Z, Chlebowski, Rowan T, Howard, Barbara V, Thomson, Cynthia A, Margolis, Karen L, Lewis, Cora E, Stefanick, Marcia L, Jackson, Rebecca D, Johnson, Karen C, Martin, Lisa W, Shumaker, Sally A, Espeland, Mark A, and Wactawski-Wende, Jean
- Subjects
Clinical Trials and Supportive Activities ,Cancer ,Aging ,Estrogen ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Good Health and Well Being ,Aged ,Cardiovascular Diseases ,Cause of Death ,Double-Blind Method ,Estrogen Replacement Therapy ,Estrogens ,Conjugated (USP) ,Female ,Follow-Up Studies ,Humans ,Medroxyprogesterone ,Middle Aged ,Mortality ,Neoplasms ,Postmenopause ,Risk ,WHI Investigators ,Medical and Health Sciences ,General & Internal Medicine - Abstract
ImportanceHealth outcomes from the Women's Health Initiative Estrogen Plus Progestin and Estrogen-Alone Trials have been reported, but previous publications have generally not focused on all-cause and cause-specific mortality.ObjectiveTo examine total and cause-specific cumulative mortality, including during the intervention and extended postintervention follow-up, of the 2 Women's Health Initiative hormone therapy trials.Design, setting, and participantsObservational follow-up of US multiethnic postmenopausal women aged 50 to 79 years enrolled in 2 randomized clinical trials between 1993 and 1998 and followed up through December 31, 2014.InterventionsConjugated equine estrogens (CEE, 0.625 mg/d) plus medroxyprogesterone acetate (MPA, 2.5 mg/d) (n = 8506) vs placebo (n = 8102) for 5.6 years (median) or CEE alone (n = 5310) vs placebo (n = 5429) for 7.2 years (median).Main outcomes and measuresAll-cause mortality (primary outcome) and cause-specific mortality (cardiovascular disease mortality, cancer mortality, and other major causes of mortality) in the 2 trials pooled and in each trial individually, with prespecified analyses by 10-year age group based on age at time of randomization.ResultsAmong 27 347 women who were randomized (baseline mean [SD] age, 63.4 [7.2] years; 80.6% white), mortality follow-up was available for more than 98%. During the cumulative 18-year follow-up, 7489 deaths occurred (1088 deaths during the intervention phase and 6401 deaths during postintervention follow-up). All-cause mortality was 27.1% in the hormone therapy group vs 27.6% in the placebo group (hazard ratio [HR], 0.99 [95% CI, 0.94-1.03]) in the overall pooled cohort; with CEE plus MPA, the HR was 1.02 (95% CI, 0.96-1.08); and with CEE alone, the HR was 0.94 (95% CI, 0.88-1.01). In the pooled cohort for cardiovascular mortality, the HR was 1.00 (95% CI, 0.92-1.08 [8.9 % with hormone therapy vs 9.0% with placebo]); for total cancer mortality, the HR was 1.03 (95% CI, 0.95-1.12 [8.2 % with hormone therapy vs 8.0% with placebo]); and for other causes, the HR was 0.95 (95% CI, 0.88-1.02 [10.0% with hormone therapy vs 10.7% with placebo]), and results did not differ significantly between trials. When examined by 10-year age groups comparing younger women (aged 50-59 years) to older women (aged 70-79 years) in the pooled cohort, the ratio of nominal HRs for all-cause mortality was 0.61 (95% CI, 0.43-0.87) during the intervention phase and the ratio was 0.87 (95% CI, 0.76-1.00) during cumulative 18-year follow-up, without significant heterogeneity between trials.Conclusions and relevanceAmong postmenopausal women, hormone therapy with CEE plus MPA for a median of 5.6 years or with CEE alone for a median of 7.2 years was not associated with risk of all-cause, cardiovascular, or cancer mortality during a cumulative follow-up of 18 years.Trial registrationclinicaltrials.gov Identifier: NCT00000611.
- Published
- 2017
32. Long‐Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative
- Author
-
Drieling, Rebecca L, LaCroix, Andrea Z, Beresford, Shirley AA, Boudreau, Denise M, Kooperberg, Charles, Chlebowski, Rowan T, Ko, Marcia G, and Heckbert, Susan R
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Clinical Sciences ,Health Sciences ,Reproductive Medicine ,Rehabilitation ,Aging ,Prevention ,Clinical Research ,Bioengineering ,Physical Injury - Accidents and Adverse Effects ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Aged ,80 and over ,Bone Density ,Bone Density Conservation Agents ,Diphosphonates ,Female ,Humans ,Osteoporotic Fractures ,Retrospective Studies ,Risk Factors ,Time Factors ,Women's Health ,fracture ,long-term bisphosphonate use ,pharmacoepidemiology ,Medical and Health Sciences ,Geriatrics ,Biomedical and clinical sciences ,Health sciences ,Psychology - Abstract
ObjectivesTo examine the association between long-term bisphosphonate use and fracture in older women at high risk of fracture.DesignRetrospective cohort.SettingWomen's Health Initiative.ParticipantsOlder women who reported at least 2 years of bisphosphonate use in 2008-09 (N = 5,120).MeasurementsExposure data were from a current medications inventory. Outcomes (hip, clinical vertebral, wrist or forearm, any clinical fracture) were ascertained annually. Using multivariate Cox proportional hazards models, the association between duration of bisphosphonate use (3-5, 6-9, 10-13 years) and fracture was estimated, using 2 years as the referent group.ResultsOn average participants were 80 years old and were followed for 3.7 ± 1.2 years. There were 127 hip, 159 wrist or forearm, 235 clinical vertebral, and 1,313 clinical fractures. In multivariate-adjusted analysis, 10 to 13 years of bisphosphonate use was associated with higher risk of any clinical fracture than 2 years of use (hazard ratio (HR) = 1.29, 95% confidence interval (CI) = 1.07-1.57). This association persisted in analyses limited to women with a prior fracture (HR = 1.30, 95% CI = 1.01-1.67) and women with no history of cancer (HR = 1.36, 95% CI = 1.10-1.68). The association of 10 to 13 years of use, compared with 2 years of use, was not statistically significant for hip (HR = 1.66, 95% CI = 0.81-3.40), clinical vertebral (HR = 1.65, 95% CI = 0.99-2.76), or wrist fracture (HR = 1.16, 95% CI = 0.67-2.00).ConclusionIn older women at high risk of fracture, 10 to 13 years of bisphosphonate use was associated with higher risk of any clinical fracture than 2 years of use. These results add to concerns about the benefit of very long-term bisphosphonate use.
- Published
- 2017
33. Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women’s Health Initiative Randomized Controlled Trial
- Author
-
Chlebowski, Rowan T, Aragaki, Aaron K, Anderson, Garnet L, Thomson, Cynthia A, Manson, JoAnn E, Simon, Michael S, Howard, Barbara V, Rohan, Thomas E, Snetselar, Linda, Lane, Dorothy, Barrington, Wendy, Vitolins, Mara Z, Womack, Catherine, Qi, Lihong, Hou, Lifang, Thomas, Fridtjof, and Prentice, Ross L
- Subjects
Breast Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,Cancer ,Complementary and Integrative Health ,Nutrition ,Prevention ,Aging ,Good Health and Well Being ,Aged ,Breast Neoplasms ,Diet ,Fat-Restricted ,Female ,Humans ,Middle Aged ,Postmenopause ,United States ,Women's Health ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Purpose Earlier Women's Health Initiative Dietary Modification trial findings suggested that a low-fat eating pattern may reduce breast cancers with greater mortality. Therefore, as a primary outcome-related analysis from a randomized prevention trial, we examined the long-term influence of this intervention on deaths as a result of and after breast cancer during 8.5 years (median) of dietary intervention and cumulatively for all breast cancers diagnosed during 16.1 years (median) of follow-up. Patients and Methods The trial randomly assigned 48,835 postmenopausal women with normal mammograms and without prior breast cancer from 1993 to 1998 at 40 US clinical centers to a dietary intervention with goals of a reduction of fat intake to 20% of energy and an increased intake of fruits, vegetables, and grains (40%; n = 19,541) or to a usual diet comparison (60%; n = 29,294). Results In the dietary group, fat intake and body weight decreased (all P < .001). During the 8.5-year dietary intervention, with 1,764 incident breast cancers, fewer deaths occurred as a result of breast cancer in the dietary group, which was not statistically significant (27 deaths [0.016% per year] v 61 deaths [0.024% per year]; hazard ratio [HR], 0.67; 95% CI, 0.43 to 1.06; P = .08). During the same period, deaths after breast cancer (n = 134) were significantly reduced (40 deaths [0.025% per year] v 94 deaths [0.038% per year]; HR, 0.65; 95% CI, 0.45 to 0.94; P = .02) by the dietary intervention. During the 16.1-year follow-up, with 3,030 incident breast cancers, deaths after breast cancer also were significantly reduced (234 deaths [0.085% per year] v 443 deaths [0.11% per year]; HR, 0.82; 95% CI, 0.70 to 0.96; P = .01) in the dietary group. Conclusion Compared with a usual diet comparison group, a low-fat dietary pattern led to a lower incidence of deaths after breast cancer.
- Published
- 2017
34. Effect of depression before breast cancer diagnosis on mortality among postmenopausal women
- Author
-
Liang, Xiaoyun, Margolis, Karen L, Hendryx, Michael, Reeves, Katherine, Wassertheil‐Smoller, Sylvia, Weitlauf, Julie, Danhauer, Suzanne C, Chlebowski, Rowan T, Caan, Bette, Qi, Lihong, Lane, Dorothy, Lavasani, Sayeh, and Luo, Juhua
- Subjects
Depression ,Breast Cancer ,Mental Health ,Cancer ,Prevention ,Clinical Research ,Aging ,Good Health and Well Being ,Aged ,Antidepressive Agents ,Breast Neoplasms ,Cause of Death ,Cohort Studies ,Comorbidity ,Depressive Disorder ,Female ,Humans ,Middle Aged ,Mortality ,Multivariate Analysis ,Neoplasm Staging ,Postmenopause ,Proportional Hazards Models ,Prospective Studies ,breast cancer ,Cox proportional hazards regression model ,depression ,mortality ,postmenopausal women ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology & Carcinogenesis - Abstract
BackgroundFew previous studies investigating depression before the diagnosis of breast cancer and breast cancer-specific mortality have examined depression measured at more than 1 time point. This study investigated the effect of depression (combining depressive symptoms alone with antidepressant use) measured at 2 time points before the diagnosis of breast cancer on all-cause mortality and breast cancer-specific mortality among older postmenopausal women.MethodsA large prospective cohort, the Women's Health Initiative, was used. The study included 3095 women with incident breast cancer who had measures of depressive symptoms and antidepressant use before their diagnosis at the baseline and at year 3. Multivariate Cox proportional hazards regression was used to estimate adjusted hazard ratios (HRs) between depression at the baseline, depression at year 3, and combinations of depression at these time points and all-cause mortality and breast cancer-specific mortality.ResultsDepression at year 3 before a breast cancer diagnosis was associated with higher all-cause mortality after adjustments for multiple covariates (HR, 1.35; 95% confidence interval [CI], 1.02-1.78). There was no statistically significant association of baseline depression and all-cause mortality or breast cancer-specific mortality whether or not depression was also present at year 3. In women with late-stage (regional- or distant-stage) breast cancer, newly developed depression at year 3 was significantly associated with both all-cause mortality (HR, 2.00; 95% CI, 1.13-3.56) and breast cancer-specific mortality (HR, 2.42; 95% CI, 1.24-4.70).ConclusionsWomen with newly developed depression before the diagnosis of breast cancer had a modestly but significantly increased risk for death from any cause and for death from breast cancer at a late stage. Cancer 2017;123:3107-15. © 2017 American Cancer Society.
- Published
- 2017
35. Use of Calcium Channel Blockers and Breast Cancer Risk in the Women's Health Initiative
- Author
-
Brasky, Theodore M, Krok-Schoen, Jessica L, Liu, Jingmin, Chlebowski, Rowan T, Freudenheim, Jo L, Lavasani, Sayeh, Margolis, Karen L, Qi, Lihong, Reding, Kerryn W, Shields, Peter G, Simon, Michael S, Wactawski-Wende, Jean, Wang, Ange, Womack, Catherine, and Manson, JoAnn E
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Health Sciences ,Oncology and Carcinogenesis ,Prevention ,Genetics ,Breast Cancer ,Aging ,Cancer ,Good Health and Well Being ,Aged ,Breast Neoplasms ,Calcium Channel Blockers ,Female ,Humans ,Middle Aged ,Risk Factors ,Women's Health ,Medical and Health Sciences ,Epidemiology ,Biomedical and clinical sciences ,Health sciences - Abstract
Background: Use of calcium channel blockers (CCBs) has been associated with increased risk of breast cancer in some, but not all, studies. Differences in reported associations from prior studies may be due, in part, to inadequate control of confounding factors.Methods: Participants were 28,561 postmenopausal women from the Women's Health Initiative who reported use of either CCBs or other antihypertensive medications (AHMs) at baseline; 1,402 incident breast cancer cases were diagnosed during 12 years of follow-up. Adjusted Cox regression models were used to estimate HRs and 95% confidence intervals (CI) for the associations between CCB use relative to other AHM use and breast cancer risk.Results: Use of CCBs was not associated with breast cancer risk (HR, 1.06; 95% CI, 0.94-1.20) relative to use of other AHMs. Associations approximated the null value when CCBs were considered by duration of use, length of action, or drug class.Conclusions: We provide additional evidence that CCBs do not influence breast cancer risk in postmenopausal women.Impact: The results from this study, which includes strong control for potential confounding factors, cast doubt on increases in risk with CCBs. Cancer Epidemiol Biomarkers Prev; 26(8); 1345-8. ©2017 AACR.
- Published
- 2017
36. Estrogen alone and health outcomes in black women by African ancestry
- Author
-
Chlebowski, Rowan T, Barrington, Wendy, Aragaki, Aaron K, Manson, JoAnn E, Sarto, Gloria, O'Sullivan, Mary J, Wu, Daniel, Cauley, Jane A, Qi, Lihong, Wallace, Robert L, and Prentice, Ross L
- Subjects
Biomedical and Clinical Sciences ,Health Services and Systems ,Public Health ,Health Sciences ,Oncology and Carcinogenesis ,Reproductive Medicine ,Rehabilitation ,Clinical Research ,Breast Cancer ,Clinical Trials and Supportive Activities ,Estrogen ,Cancer ,Aging ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Black or African American ,Aged ,Breast Neoplasms ,Estrogen Replacement Therapy ,Estrogens ,Estrogens ,Conjugated (USP) ,Female ,Humans ,Hysterectomy ,Incidence ,Middle Aged ,Postmenopause ,Postoperative Period ,Proportional Hazards Models ,Treatment Outcome ,United States ,African ancestry ,Black women ,Estrogen alone ,Randomized trial ,Women's Health Initiative ,Medical and Health Sciences ,Obstetrics & Reproductive Medicine ,Biomedical and clinical sciences ,Health sciences ,Psychology - Abstract
ObjectiveIn postmenopausal black women in the Women's Health Initiative randomized trial, estrogen alone reduced breast cancers but its comprehensive influence on health outcomes in black women is unknown. Therefore, we examined this issue in the Women's Health Initiative overall and by African ancestry.MethodsA total of 1,616 black women with prior hysterectomy, including 1,061 with percent African ancestry determination, at 40 US centers were randomly assigned to conjugated equine estrogen (0.625 mg/d) or placebo for 7.2 years' (median) intervention with 13 years' cumulative follow-up. Coronary heart disease (CHD) and breast cancer were primary efficacy and safety outcomes, respectively. A global index also included stroke, colorectal cancer, hip fracture, pulmonary embolism, and death.ResultsBlack women in the estrogen-alone group compared with black women in the placebo group had fewer breast cancers (17 vs 40, hazard ratio [HR] 0.47, 95% CI 0.26-0.82). In women with more than 80% African ancestry, breast cancer HR was lower (0.32, 95% CI 0.12-0.86, trend P = 0.04 for ancestry effect). Most other outcomes including CHD, stroke, hip fracture, and the global index were null with estrogen use in black women; a global index effect was more favorable in younger black women (HR 0.65, 95% CI 0.43-0.98).ConclusionsIn black postmenopausal women with prior hysterectomy, estrogen alone significantly reduced breast cancer incidence with no adverse influence on CHD, venous thromboembolism, or all-cause mortality. Favorable estrogen-alone global index effects in younger black women warrant further study.
- Published
- 2017
37. Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women.
- Author
-
Banegas, Matthew P, John, Esther M, Slattery, Martha L, Gomez, Scarlett Lin, Yu, Mandi, LaCroix, Andrea Z, Pee, David, Chlebowski, Rowan T, Hines, Lisa M, Thompson, Cynthia A, and Gail, Mitchell H
- Subjects
Humans ,Carcinoma ,Ductal ,Breast ,Breast Neoplasms ,Incidence ,Area Under Curve ,Logistic Models ,Risk Assessment ,Risk Factors ,Case-Control Studies ,Longitudinal Studies ,ROC Curve ,Adult ,Aged ,Middle Aged ,Hispanic Americans ,Women's Health ,United States ,Female ,Carcinoma ,Ductal ,Breast ,Oncology And Carcinogenesis ,Oncology & Carcinogenesis ,Oncology and Carcinogenesis - Abstract
BackgroundThere is no model to estimate absolute invasive breast cancer risk for Hispanic women.MethodsThe San Francisco Bay Area Breast Cancer Study (SFBCS) provided data on Hispanic breast cancer case patients (533 US-born, 553 foreign-born) and control participants (464 US-born, 947 foreign-born). These data yielded estimates of relative risk (RR) and attributable risk (AR) separately for US-born and foreign-born women. Nativity-specific absolute risks were estimated by combining RR and AR information with nativity-specific invasive breast cancer incidence and competing mortality rates from the California Cancer Registry and Surveillance, Epidemiology, and End Results program to develop the Hispanic risk model (HRM). In independent data, we assessed model calibration through observed/expected (O/E) ratios, and we estimated discriminatory accuracy with the area under the receiver operating characteristic curve (AUC) statistic.ResultsThe US-born HRM included age at first full-term pregnancy, biopsy for benign breast disease, and family history of breast cancer; the foreign-born HRM also included age at menarche. The HRM estimated lower risks than the National Cancer Institute's Breast Cancer Risk Assessment Tool (BCRAT) for US-born Hispanic women, but higher risks in foreign-born women. In independent data from the Women's Health Initiative, the HRM was well calibrated for US-born women (observed/expected [O/E] ratio = 1.07, 95% confidence interval [CI] = 0.81 to 1.40), but seemed to overestimate risk in foreign-born women (O/E ratio = 0.66, 95% CI = 0.41 to 1.07). The AUC was 0.564 (95% CI = 0.485 to 0.644) for US-born and 0.625 (95% CI = 0.487 to 0.764) for foreign-born women.ConclusionsThe HRM is the first absolute risk model that is based entirely on data specific to Hispanic women by nativity. Further studies in Hispanic women are warranted to evaluate its validity.
- Published
- 2017
38. Cardiovascular Disease After Aromatase Inhibitor Use
- Author
-
Haque, Reina, Shi, Jiaxiao, Schottinger, Joanne E, Chung, Joanie, Avila, Chantal, Amundsen, Britta, Xu, Xiaoqing, Barac, Ana, and Chlebowski, Rowan T
- Subjects
Aging ,Clinical Research ,Estrogen ,Heart Disease ,Cancer ,Breast Cancer ,Prevention ,Cardiovascular ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Aged ,Aromatase Inhibitors ,Breast Neoplasms ,Cardiovascular Diseases ,Female ,Humans ,Middle Aged ,Proportional Hazards Models ,Risk Factors ,Survivors ,Tamoxifen ,Oncology and Carcinogenesis ,Public Health and Health Services - Abstract
ImportanceCardiovascular disease (CVD) is an important cause of death in older patients with breast cancer. However, limited information exists on the long-term effect of aromatase inhibitor (AI) use on CVD risk in breast cancer survivors. To this point, no other population-based studies have been able to adjust for CVD risk factors or cardiovascular medications.ObjectiveTo determine the long-term influence of adjuvant endocrine therapies on CVD in a cohort of postmenopausal breast cancer survivors in analyses that accounted for major CVD risk factors, medication use, chemotherapy, and radiotherapy.Design, setting, and participantsA retrospective cohort of postmenopausal women with breast cancer diagnosed from January 1, 1991, to December 31, 2010, and followed up through December 31, 2011 (maximum, 21 years [72 886 person-years]), was evaluated using records from a managed care organization with nearly 20 community hospitals in California. A total of 13 273 postmenopausal women with hormone receptor-positive breast cancer without prior CVD were included. Cardiovascular disease incidence was compared across endocrine therapy categories. Information on demographics, comorbidity, medication, use, and CVD risk was captured from electronic health records. Multivariate Cox proportional hazards models using time-dependent endocrine drug use variables and propensity scores were conducted. Data analysis was conducted from September 15, 2014, to February 1, 2016.ExposuresWomen were grouped by endocrine therapy status (tamoxifen citrate only, AI only, both, or neither).Main outcomes and measuresPerson-year rates of CVD for each therapy group.ResultsDuring 72 886 person-years in 13 273 women (mean [SD] age, 66.8 [8.1] years) with follow-up through 2011, we observed 3711 CVD events. In multivariable analyses (reported as hazard ratio [95% CI]), AI-only users had a similar risk of cardiac ischemia (myocardial infarction and angina) (adjusted, 0.97 [0.78-1.22]) and stroke (adjusted, 0.97 [0.70-1.33]) as tamoxifen-only users (reference). However, we found an increased risk of other CVD (dysrhythmia, valvular dysfunction, and pericarditis) (adjusted, 1.29 [1.11-1.50]) in women who used AIs only or sequentially after tamoxifen (1.26 [1.09-1.45]) vs tamoxifen (reference) as well nonhormone users (1.18 [1.02-1.35]).Conclusions and relevanceThe risk of the most serious cardiovascular events (cardiac ischemia or stroke) was not elevated in AI-only users compared with tamoxifen users. The finding that other CVD events combined were greater in AI users requires further study.
- Published
- 2016
39. Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk
- Author
-
Schonberg, Mara A, Li, Vicky W, Eliassen, A Heather, Davis, Roger B, LaCroix, Andrea Z, McCarthy, Ellen P, Rosner, Bernard A, Chlebowski, Rowan T, Hankinson, Susan E, Marcantonio, Edward R, and Ngo, Long H
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Prevention ,Cancer ,Behavioral and Social Science ,Breast Cancer ,Good Health and Well Being ,Adult ,Breast Neoplasms ,Cause of Death ,Female ,Follow-Up Studies ,Humans ,Middle Aged ,Models ,Statistical ,Mortality ,Population Surveillance ,Postmenopause ,Prognosis ,Reproducibility of Results ,Risk Assessment ,Risk Factors ,Breast cancer prediction ,Competing risks ,Older ,Clinical Sciences ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
PurposeAccurate risk assessment is necessary for decision-making around breast cancer prevention. We aimed to develop a breast cancer prediction model for postmenopausal women that would take into account their individualized competing risk of non-breast cancer death.MethodsWe included 73,066 women who completed the 2004 Nurses' Health Study (NHS) questionnaire (all ≥57 years) and followed participants until May 2014. We considered 17 breast cancer risk factors (health behaviors, demographics, family history, reproductive factors) and 7 risk factors for non-breast cancer death (comorbidities, functional dependency) and mammography use. We used competing risk regression to identify factors independently associated with breast cancer. We validated the final model by examining calibration (expected-to-observed ratio of breast cancer incidence, E/O) and discrimination (c-statistic) using 74,887 subjects from the Women's Health Initiative Extension Study (WHI-ES; all were ≥55 years and followed for 5 years).ResultsWithin 5 years, 1.8 % of NHS participants were diagnosed with breast cancer (vs. 2.0 % in WHI-ES, p = 0.02), and 6.6 % experienced non-breast cancer death (vs. 5.2 % in WHI-ES, p
- Published
- 2016
40. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer
- Author
-
Drieling, Rebecca L, LaCroix, Andrea Z, Beresford, Shirley AA, Boudreau, Denise M, Kooperberg, Charles, Chlebowski, Rowan T, Gass, Margery, Crandall, Carolyn J, Womack, Catherine R, and Heckbert, Susan R
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Health Sciences ,Oncology and Carcinogenesis ,Cancer ,Breast Cancer ,Aging ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Aged ,Bone Density Conservation Agents ,Breast Neoplasms ,Diphosphonates ,Female ,Fractures ,Bone ,Humans ,Longitudinal Studies ,Postmenopause ,Proportional Hazards Models ,Risk Factors ,Time Factors ,Women's Health ,Breast cancer ,Fracture ,Oral bisphosphonate ,Postmenopausal ,Medical and Health Sciences ,Obstetrics & Reproductive Medicine ,Biomedical and clinical sciences ,Health sciences ,Psychology - Abstract
ObjectiveThe aim of the study was to examine the association of long-term oral bisphosphonate use, compared with short-term use, with fracture risk among postmenopausal women with breast cancer.MethodsWe studied 887 postmenopausal women who were enrolled to the Women's Health Initiative from 1993 to 1998, diagnosed with breast cancer after enrollment, and reported current oral bisphosphonate use of 2 years or more on a medication inventory administered in 2008 to 2009. The outcome of any clinical fracture was ascertained by self-report on an annual study form; a subset of fractures was confirmed with medical records. Women were followed from completion of the medication inventory until 2014. The association between duration of bisphosphonate use reported on the medication inventory and fracture was estimated using multivariate Cox proportional hazards survival models that compared 4 to 7 years and 8 or more years of bisphosphonate use with 2 to 3 years of use.ResultsOn average, women were 76 years of age and were followed for 3.7 (SD 1.1) years. There were 142 clinical fractures. In the multivariate-adjusted analysis for fracture risk factors, 8 or more years of bisphosphonate use was associated with higher risk of fracture compared with 2 to 3 years of use (hazard ratio, 1.67 [95% CI, 1.06-2.62]). There was no significant association of 4 to 7 years of use with fracture.ConclusionsBisphosphonate use of 8 or more years was associated with higher risk of any clinical fracture compared with 2 to 3 years of use. Our findings raise concern about potential harm or decreased effectiveness of long-term bisphosphonate use on fracture risk. The findings warrant confirmatory studies.
- Published
- 2016
41. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative.
- Author
-
Drieling, Rebecca L, LaCroix, Andrea Z, Beresford, Shirley AA, Boudreau, Denise M, Kooperberg, Charles, Chlebowski, Rowan T, Gass, Margery, Crandall, Carolyn J, Womack, Catherine R, and Heckbert, Susan R
- Subjects
Humans ,Breast Neoplasms ,Diphosphonates ,Proportional Hazards Models ,Risk Factors ,Longitudinal Studies ,Postmenopause ,Time Factors ,Aged ,Women's Health ,Female ,Bone Density Conservation Agents ,Fractures ,Bone ,Breast cancer ,Fracture ,Oral bisphosphonate ,Postmenopausal ,Fractures ,Bone ,Medical And Health Sciences ,Obstetrics & Reproductive Medicine ,Medical and Health Sciences - Abstract
ObjectiveThe aim of the study was to examine the association of long-term oral bisphosphonate use, compared with short-term use, with fracture risk among postmenopausal women with breast cancer.MethodsWe studied 887 postmenopausal women who were enrolled to the Women's Health Initiative from 1993 to 1998, diagnosed with breast cancer after enrollment, and reported current oral bisphosphonate use of 2 years or more on a medication inventory administered in 2008 to 2009. The outcome of any clinical fracture was ascertained by self-report on an annual study form; a subset of fractures was confirmed with medical records. Women were followed from completion of the medication inventory until 2014. The association between duration of bisphosphonate use reported on the medication inventory and fracture was estimated using multivariate Cox proportional hazards survival models that compared 4 to 7 years and 8 or more years of bisphosphonate use with 2 to 3 years of use.ResultsOn average, women were 76 years of age and were followed for 3.7 (SD 1.1) years. There were 142 clinical fractures. In the multivariate-adjusted analysis for fracture risk factors, 8 or more years of bisphosphonate use was associated with higher risk of fracture compared with 2 to 3 years of use (hazard ratio, 1.67 [95% CI, 1.06-2.62]). There was no significant association of 4 to 7 years of use with fracture.ConclusionsBisphosphonate use of 8 or more years was associated with higher risk of any clinical fracture compared with 2 to 3 years of use. Our findings raise concern about potential harm or decreased effectiveness of long-term bisphosphonate use on fracture risk. The findings warrant confirmatory studies.
- Published
- 2016
42. Temporal Associations and Outcomes of Breast Cancer and Heart Failure in Postmenopausal Women
- Author
-
Lam, Phillip H., Barac, Ana, Nohria, Anju, Reding, Kerryn W., Najjar, Samer S., Fonarow, Gregg C., Pan, Kathy, Sheriff, Helen, Morgan, Charity J., Chlebowski, Rowan T., Klein, Liviu, Eaton, Charles B., Howard, Barbara V., Ahmed, Ali, and Mohammed, Selma F.
- Published
- 2020
- Full Text
- View/download PDF
43. Low-fat dietary pattern and global cognitive function: Exploratory analyses of the Women's Health Initiative (WHI) randomized Dietary Modification trial
- Author
-
Chlebowski, Rowan T., Rapp, Steve, Aragaki, Aaron K., Pan, Kathy, Neuhouser, Marian L., Snetselaar, Linda G., Manson, JoAnn E., Wactawski-Wende, Jean, Johnson, Karen C., Hayden, Kathleen, Baker, Laura D., Henderson, Victor W., Garcia, Lorena, Qi, Lihong, and Prentice, Ross L.
- Published
- 2020
- Full Text
- View/download PDF
44. Menopausal Hormone Therapy and Breast Cancer
- Author
-
Chlebowski, Rowan T. and Manson, JoAnn E.
- Published
- 2022
- Full Text
- View/download PDF
45. Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention
- Author
-
Chlebowski, Rowan T and Budoff, Matthew J
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Health Sciences ,Oncology and Carcinogenesis ,Cancer ,Aromatase Inhibitors ,Breast Neoplasms ,Female ,Humans ,Nitriles ,Triazoles ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Published
- 2016
46. Performance of the Breast Cancer Risk Assessment Tool Among Women Aged 75 Years and Older
- Author
-
Schonberg, Mara A, Li, Vicky W, Eliassen, A Heather, Davis, Roger B, LaCroix, Andrea Z, McCarthy, Ellen P, Rosner, Bernard A, Chlebowski, Rowan T, Rohan, Thomas E, Hankinson, Susan E, Marcantonio, Edward R, and Ngo, Long H
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Prevention ,Aging ,Breast Cancer ,Clinical Research ,Human Genome ,Genetics ,Cancer ,Good Health and Well Being ,Age Factors ,Aged ,Aged ,80 and over ,Breast Neoplasms ,Cause of Death ,Early Detection of Cancer ,Female ,Follow-Up Studies ,Humans ,Incidence ,Mammography ,Mass Screening ,Middle Aged ,Models ,Statistical ,Odds Ratio ,Risk Assessment ,Risk Factors ,United States ,Whites ,Women's Health ,White People ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundThe Breast Cancer Risk Assessment Tool (BCRAT, "Gail model") is commonly used for breast cancer prediction; however, it has not been validated for women age 75 years and older.MethodsWe used Nurses' Health Study (NHS) data beginning in 2004 and Women's Health Initiative (WHI) data beginning in 2005 to compare BCRAT's performance among women age 75 years and older with that in women age 55 to 74 years in predicting five-year breast cancer incidence. BCRAT risk factors include: age, race/ethnicity, age at menarche, age at first birth, family history, history of benign breast biopsy, and atypia. We examined BCRAT's calibration by age by comparing expected/observed (E/O) ratios of breast cancer incidence. We examined discrimination by computing c-statistics for the model by age. All statistical tests were two-sided.ResultsSeventy-three thousand seventy-two NHS and 97 081 WHI women participated. NHS participants were more likely to be non-Hispanic white (96.2% vs 84.7% in WHI, P < .001) and were less likely to develop breast cancer (1.8% vs 2.0%, P = .02). E/O ratios by age in NHS were 1.16 (95% confidence interval [CI] = 1.09 to 1.23, age 57-74 years) and 1.31 (95% CI = 1.18 to 1.45, age ≥ 75 years, P = .02), and in WHI 1.03 (95% CI = 0.97 to 1.09, age 55-74 years) and 1.10 (95% CI = 1.00 to 1.21, age ≥ 75 years, P = .21). E/O ratio 95% confidence intervals crossed one among women age 75 years and older when samples were limited to women who underwent mammography and were without significant illness. C-statistics ranged between 0.56 and 0.58 in both cohorts regardless of age.ConclusionsBCRAT accurately predicted breast cancer for women age 75 years and older who underwent mammography and were without significant illness but had modest discrimination. Models that consider individual competing risks of non-breast cancer death may improve breast cancer risk prediction for older women.
- Published
- 2016
47. Reply to W Willett
- Author
-
Prentice, Ross L., primary, Neuhouser, Marian L., additional, and Chlebowski, Rowan T., additional
- Published
- 2023
- Full Text
- View/download PDF
48. Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival
- Author
-
Dauphine, Christine, Moazzez, Ashkan, Neal, Jasmin C., Chlebowski, Rowan T., and Ozao-Choy, Junko
- Published
- 2020
- Full Text
- View/download PDF
49. Breast Cancer Outcomes in a Racially and Ethnically Diverse Cohort of Insured Women
- Author
-
Haque, Reina, Xu, Xiaoqing, Shi, Jiaxiao, Kwan, Marilyn L., and Chlebowski, Rowan T.
- Published
- 2018
50. The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women’s Health Initiative
- Author
-
Yung, Rachel, Ray, Roberta M., Roth, Joshua, Johnson, Lisa, Warnick, Greg, Anderson, Garnet L., Kroenke, Candyce H., Chlebowski, Rowan T., Simon, Michael S., Fung, Chunkit, Pan, Kathy, Wang, Di, Barrington, Wendy E., and Reding, Kerryn W.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.